4D Molecular officer plans $0.8M stock sale

Officer David Kirn files a Form 144 to sell up to 58,333 FDMT shares under a Rule 10b5-1 selling plan, following several recent stock sales.

Available on EDGAR 09/14/2026 - 06:00 PM EDT Accepted by SEC EDGAR 09/14/2026 - 06:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. (FDMT) reports that officer David Kirn has filed a Form 144 to sell up to 58,333 shares of Class A Common Stock through Goldman Sachs & Co. LLC, with an aggregate market value of $802,662.08, based on 55,244,211 shares outstanding of the same class. The shares were acquired from the issuer in a private transaction on December 15, 2020. The filing also lists prior sales of FDMT Class A Common Stock by Kirn over the past three months under a pre-established selling plan intended to comply with Rule 10b5-1(c).

Key Figures

Shares to be sold: 58,333 shares Aggregate market value of securities to be sold: $802,662.08 Shares outstanding of same class: 55,244,211 shares +3 more

6 metrics

Shares to be sold 58,333 shares Class A Common Stock covered by the Form 144 notice

Aggregate market value of securities to be sold $802,662.08 Estimated value for the 58,333 FDMT shares in the Form 144

Shares outstanding of same class 55,244,211 shares Class A Common Stock outstanding used for Rule 144 computation

Sale on June 22, 2026 114,746 shares for $1,200,851.31 FDMT Class A Common Stock sold by David Kirn in prior 3 months

Sale on August 19, 2026 (largest single block) 50,000 shares for $799,565.00 FDMT Class A Common Stock sold by David Kirn

Form 144 notice date September 14, 2026 Date the Form 144 notice is dated

Key Terms

Rule 144, Rule 10b5-1(c), selling plan, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1(c) regulatory

"a selling plan dated 01/09/2026 that is intended to comply with Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

selling plan financial

"The sales of shares set forth herein are made in connection with a selling plan dated 01/09/2026"

aggregate market value financial

"Class A Common | Goldman Sachs & Co. LLC ... | 58333 | 802662.08 | 55244211"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for 4D Molecular Therapeutics (FDMT)?

The filing discloses that officer David Kirn plans to sell up to 58,333 shares of FDMT Class A Common Stock through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $802,662.08, under Rule 144.

How many FDMT shares is David Kirn planning to sell in this Form 144?

David Kirn is planning to sell up to 58,333 shares of 4D Molecular Therapeutics Class A Common Stock, as stated in the Form 144 Securities Information section.

What is the aggregate market value of the FDMT shares covered by this Form 144?

The aggregate market value of the FDMT Class A Common Stock covered by this Form 144 is reported as $802,662.08 for the 58,333 shares to be sold.

Were recent FDMT share sales by David Kirn disclosed in this Form 144?

Yes. The notice lists past three-month sales including 124,15 shares for $124,722.33 on August 3, 2026, 114,746 shares for $1,200,851.31 on June 22, 2026, and several other transactions in July and August 2026.

Is the planned FDMT stock sale under a Rule 10b5-1 plan?

Yes. The remarks state that the sales of shares are made in connection with a selling plan dated January 9, 2026 that is intended to comply with Rule 10b5-1(c).

How many FDMT shares are reported as outstanding in this Form 144?

The Form 144 indicates that there are 55,244,211 shares of the same class of FDMT securities outstanding, used in the Rule 144 calculation context.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001834021
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	4D Molecular Therapeutics, Inc.
SEC File Number	001-39782
Address of Issuer	5858 Horton Street Suite 455 Emeryville CALIFORNIA 94608
Phone	1-510-505-2680
Name of Person for Whose Account the Securities are To Be Sold	David Kirn
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	58333	802662.08	55244211	09/14/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	12/15/2020	Acquired from issuer in private transaction	Issuer			58333	12/15/2020	None

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	08/03/2026	12415	124722.33
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	06/22/2026	114746	1200851.31
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	07/09/2026	42608	548177.48
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	07/10/2026	15725	189233.08
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	08/04/2026	26842	274596.34
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	08/19/2026	50000	799565
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	08/19/2026	19076	288707.63

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 01/09/2026 that is intended to comply with Rule 10b5-1(c).
Date of Notice	09/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of David Kirn
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)